Aortech Share Discussion Threads

[the stigologist] 19/2/2018 20:59

Chart is looking very nicely poised and thankfully the numpties talking about 30p are too embarrassed/cowardly to post

[investordave] 19/2/2018 15:47

No but going to buy the 5,000 shares as soon as I have funds available later this week. I think the transaction shown today is a sell but the volume is so low that I really don't think it matters.

[cyberbub] 19/2/2018 15:43

Are you saying that's your 5k trade and it's a buy?

[investordave] 19/2/2018 11:23

Yep. Please wake me up when there's some action.

[davisc5] 19/2/2018 10:20

Snooze day by the looks of it

[k1ngkonggb] 18/2/2018 19:06

Lol....cool...you old rogue!!!

[coolhandfluke] 18/2/2018 18:57

I am in the process of raising funds for a £300 million take-over. I just need a further £299,999,999 and the fireworks will begin.

[turbotrader2] 18/2/2018 15:57

Could next week be the week?

[bones] 18/2/2018 10:17

For info:

AOR’s Elast-Eon and ECSiL as displayed on Biomerics’ website:

[the stigologist] 18/2/2018 10:13

Biomerics is one route to upside. The other is licensing IP to other companies after taking back non performing licences.


Our manufacturing licensee, Biomerics concluded a licence for Elast-Eon™ earlier this year together with a long term supply agreement. There are currently a number of companies evaluating Elast-Eon™ which if succesful may lead to other licences. Biomerics adopts a different approach to licensing to that which AorTech has historically pursued. AorTech signed a number of licences with very small/development companies long before products were ready for market launch. As a result, other than annual maintenance fees, the revenues from those licences depended upon future product launches. By contrast, Biomerics is focussed on volume supply and near term success.



Some historic licences signed by the Company have not generated value for AorTech and have only resulted in the Elast-Eon™ material not being exploited in the field of the licence. An example of this was the licence for breast implants signed in 2011. Since that time, AorTech's technology has not been incorporated into any new device nor generated any revenue for AorTech despite maintaining an IP portfolio in this arena. Your Board still believes there to be substantial benefits in utilising Elast-Eon™ technology in cosmetic and reconstructive surgery and as a result recently terminated this licence in order to pursue other opportunities in the field.



In a similar manner, we have sought to withdraw from non-performing licences. We recently served notice of termination on CardioSolutions, Inc which had licenced polymer for use in heart valve repair, as two annual minimum payments had been missed.

[bbr391] 18/2/2018 08:37

Great news should be with Aortech soon .
Biomerics are doing well.

Bottoms Up .

[blueball] 16/2/2018 19:38

Buy.


The market is telling you of a new profit.Do not miss this bullish opportunity.

[the stigologist] 16/2/2018 15:43

There were people willing to sell to me at 1.7 to 1.8p on PYC the day they announced their transformational Merck deal. The next day there were people selling at 3 and 4p. The next day people were paying 30p!

Don't bother what other people do.

[investordave] 16/2/2018 15:37

Hopefully the sellers will have made big profits. Otherwise, why sell at this low level?

[mikeh30] 16/2/2018 15:20

Harder to buy now can only get quotes for 2500

[turbotrader2] 16/2/2018 15:08

A few more buys will see it there

[bones] 16/2/2018 14:24

Always happy for a 55p finish though Dave :)

[investordave] 16/2/2018 14:24

A sale. Eek. Shame on you whoever you are.

[investordave] 16/2/2018 14:14

All fair points bones.

[bones] 16/2/2018 14:10

Daily finishes are irrelevant for this company. Price moves erratically both ways on small volume so got to focus on the business development and the share price taking care of itself :)

[investordave] 16/2/2018 14:08

55p to buy would be a great finish for me.

[blueball] 16/2/2018 13:58

Can see this finishing at 55p Dave.

[investordave] 16/2/2018 13:57

The MMs will be getting short of stock soon.